Our investors share our vision and passion and bring deep expertise and experience in developing promising companies such as Artios.
Artios has recently raised $153 million (£110 million) in July 2021 in a Series C financing. Again, the financing was oversubscribed, and is led by Omega Funds and TCG Crossover; we now have a total of 20 investors in Artios. Our new investors are Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital.
These new investors join existing investors Arix Bioscience plc, SV Health Investors, Andera Partners, LSP (Life Sciences Partners), M Ventures, Pfizer Ventures, IP Group plc, and Novartis Venture Fund who also continue to support Artios through their participation.
In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, will join Artios’ Board of Directors.
In August 2018, Artios raised $84 million (£65 million) in a Series B financing. The financing was significantly oversubscribed and was led by Andera Partners and LSP, with participation by additional new investors Pfizer Ventures and Novartis Bioventures. Existing shareholders AbbVie Ventures, Arix Bioscience, IP Group, Merck Ventures and SV Health Investors also participated in the fundraise.
This financing follows a $33 million (£25 million) Series A fundraise that was completed in September 2016.
Artios’ strategy is to work with the foremost DDR researchers globally to identify and develop the best DDR programmes. The Company has developed strong partnerships that enable it to accelerate identification and development of novel DDR inhibitors.
Through collaboration and in-licensing opportunities Artios has built an exciting portfolio of DDR programmes. Working with world leaders in DNA repair research, including Professor Simon Boulton at the Francis Crick Institute, London, the Company is able to rapidly identify the biology and clinical positioning of DDR targets for the benefit of cancer patients.
Research collaboration agreements with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and Masaryk University in the Czech Republic have allowed access to a number of first-in-class DDR programmes. Under research agreements, Artios has the option to in-license further promising programmes, including collaborating with Masaryk University on the discovery of products targeting key nucleases involved in DNA repair pathways. Artios has a number of collaborations with leading DDR groups and academics from around the world giving access to research and expertise in DDR.
Reach out to us.